Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05868525 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).

Study acronym: BASA
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 2025 to Dec 2026v8
  2. Start date changed from estimate of Dec 2024 to Aug 23, 2023v7
  3. Start date: Jul 2024 to Dec 2024
    • Primary and study completion dates: Jul 2025 to Dec 2025
    v6
  4. Start date: Apr 2024 to Jul 2024
    • Primary completion date: Apr 1, 2025 to Jul 2025
    • Study completion date: Aug 1, 2025 to Jul 2025
    v5
  5. Start date: Nov 2023 to Apr 2024v4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v3
  2. Start date: Jul 1, 2023 to Nov 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Loma Linda University
63 trials monitored
See 3 trials at risk
Stroke
3,531 trials monitored
See 153 trials at risk
The goal of this clinical trial is to compare difference between Aspirin 81 mg and Aspirin 325 mg in preventing strokes in patients with head and neck vessels injury. The main questions it aims to answer are: * If Aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessels injury is not lower than and Aspirin 325 mg. * If rate of hemorrhagic complications in patients with head and neck vessels injury taking Aspirin 81 mg is not higher than patients that take Aspirin 325 mg.
Trial Details
NCT Number NCT05868525
Lead Sponsor Loma Linda University
Conditions
(from sponsor)		 Blunt Cerebrovascular Injury
Enrollment 98 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov